December 21st, 2011 by admin
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for tofacitinib (development code CP-690,550), an investigational novel, oral JAK inhibitor being studied for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). The FDA has provided an anticipated [...]
Read the rest »
December 17th, 2011 by admin
SAN MATEO, Calif., Dec 15, 2011 (GlobeNewswire via COMTEX) –NeurogesX, Inc. /quotes/zigman/105099/quotes/nls/ngsx NGSX -5.05% , a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today confirmed that the Division of Anesthesia, Analgesia and Addiction Products (DAAAP) of the U.S. Food and Drug Administration (FDA) has scheduled an Anesthetic and Analgesic Drug Products [...]
Read the rest »
December 8th, 2011 by admin
SCOTTSDALE, Ariz.–(BUSINESS WIRE)–A new treatment for those with constant migraine headaches has emerged from an unlikely source. Botox, or Botulinum toxin type A, the popular wrinkle relaxer and plastic surgeon office staple, is being used to help those who suffer from migraines. “By using Botox to treat our patients’ incapacitating migraines, we’re able to give [...]
Read the rest »
November 27th, 2011 by admin
Vertiflex, the San Clemente, Calif.-based manufacturer of the Superion device, conducts nationwide advertising of the trial, which has been approved by the Food and Drug Administration, Haley said.Once enrolled in the study, a patient is implanted, via an outpatient procedure, with either the Superion device or another device called X-STOP, which has already received approval [...]
Read the rest »
Tags: 
